OBJECTIVE: To study fracture risk associated with use of systemic vitamin A analogue (isotretinoin and acitretin) treatment. DESIGN: Case-control study. SETTING: Nationwide registry. PARTICIPANTS: A total of 124 655 patients with fractures (cases) and 373 962 age- and sex-matched controls. Main Outcome Measure Incidence of fractures in patients with and without exposure to systemic vitamin A analogues. Confounder control was performed for social variables, contacts with hospitals and general practitioners, alcoholism, and a number of other variables known to potentially affect fracture risk, including use of systemic, intramuscular, and topical corticosteroids and antiepileptic drugs and comorbid conditions. RESULTS: No trend in risk of any fracture or of hip, forearm, or spine fractures was present with increasing doses or durations of treatment with vitamin A analogues. Subdividing vitamin A analogues into isotretinoin and acitretin did not change the results. CONCLUSION: Risk of fracture is not associated with vitamin A analogue treatment.
OBJECTIVE: To study fracture risk associated with use of systemic vitamin A analogue (isotretinoin and acitretin) treatment. DESIGN: Case-control study. SETTING: Nationwide registry. PARTICIPANTS: A total of 124 655 patients with fractures (cases) and 373 962 age- and sex-matched controls. Main Outcome Measure Incidence of fractures in patients with and without exposure to systemic vitamin A analogues. Confounder control was performed for social variables, contacts with hospitals and general practitioners, alcoholism, and a number of other variables known to potentially affect fracture risk, including use of systemic, intramuscular, and topical corticosteroids and antiepileptic drugs and comorbid conditions. RESULTS: No trend in risk of any fracture or of hip, forearm, or spine fractures was present with increasing doses or durations of treatment with vitamin A analogues. Subdividing vitamin A analogues into isotretinoin and acitretin did not change the results. CONCLUSION: Risk of fracture is not associated with vitamin A analogue treatment.
Authors: G L Ambrosini; A P Bremner; A Reid; D Mackerras; H Alfonso; N J Olsen; A W Musk; N H de Klerk Journal: Osteoporos Int Date: 2012-09-18 Impact factor: 4.507
Authors: Andrea L Zaenglein; Moise L Levy; Nicole S Stefanko; Latanya T Benjamin; Anna L Bruckner; Keith Choate; Brittany G Craiglow; John J DiGiovanna; Lawrence F Eichenfield; Peter Elias; Philip Fleckman; Leslie P Lawley; Richard A Lewis; Anne W Lucky; Erin F Mathes; Leonard M Milstone; Amy S Paller; Sonali S Patel; Dawn H Siegel; Joyce Teng; Sherry A Tanumihardjo; Lauren Thaxton; Mary L Williams Journal: Pediatr Dermatol Date: 2020-11-10 Impact factor: 1.588